As a second-line zipalertinib filing approaches, Otsuka goes earlier and broader.
ApexOnco Front Page
Recent articles
Summit and Nuvalent have scored prized plenary spots.
NT-125 is discontinued, while two key Datroway readouts are delayed.
A Pfizer cast-off could become the company's first marketed drug.
Meanwhile, investors await key clinical data.
Tiragolumab failed the Skyscraper-14 and 03 studies, Roche quietly reveals.
But BeOne canned its alcestobart deal in May.
The company claims a 69% response rate with iSCIB1+, but only in a “target population”.
